Flunarizine in the treatment of vertigo

Experience with flunarizine, a selective calcium-entry blocker, in the treatment of dizziness is reviewed. Clinical efficacy was predicted in pharmacological studies both in rabbits and humans: torsion swing or caloric induced nystagmus were significantly suppressed by flunarizine. Open therapeutic...

Full description

Saved in:
Bibliographic Details
Published inJournal of laryngology and otology Vol. 97; no. 8; p. 697
Main Authors Wouters, L, Amery, W, Towse, G
Format Journal Article
LanguageEnglish
Published England 01.08.1983
Subjects
Animals
Calcium Channel Blockers - therapeutic use
Cerebrovascular Disorders - drug therapy
Cinnarizine - analogs & derivatives
Cinnarizine - therapeutic use
Clinical Trials as Topic
Double-Blind Method
Flunarizine
Humans
Labyrinth Diseases - drug therapy
Piperazines - therapeutic use
Rabbits
Vertebrobasilar Insufficiency - drug therapy
Vertigo - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Experience with flunarizine, a selective calcium-entry blocker, in the treatment of dizziness is reviewed. Clinical efficacy was predicted in pharmacological studies both in rabbits and humans: torsion swing or caloric induced nystagmus were significantly suppressed by flunarizine. Open therapeutic findings, using clinical and electronystagmographic or audiographic assessments as well, showed that flunarizine is of benefit to patients with vertigo of labyrinthine as well as of cerebrovascular origin. These results were confirmed in double-blind controlled trials. Flunarizine, either started with a loading dose gradually decreased thereafter, or given at a fixed 10 mg. dose schedule was proven to produce rapid improvement of dizziness and unsteadiness and to be tolerated very well.
ISSN:0022-2151
DOI:10.1017/S0022215100094858